TUSTIN, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it will present at the BIO CEO conference at the Waldorf Astoria Hotel in New York City on Wednesday, February 15, 2006 at 2:30 pm EST in the Louis XVI Center/West room.
Peregrine CEO and president Steven W. King will provide an update and review of recent corporate developments.
Mr. King’s presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s Website at www.peregrineinc.com. A replay will be available on the Peregrine website and will be archived for approximately 90 days.
About Peregrine
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin(TM) and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Investors Media Brod & Schaffer Stephen Gendel (800) 987-8256 GendeLLindheim BioCom Partners ir@peregrineinc.com (212) 918-4650
Peregrine Pharmaceuticals, Inc.
CONTACT: Investors, Brod & Schaffer, +1-800-987-8256, ir@peregrineinc.com,for Peregrine Pharmaceuticals, Inc.; or Media, Stephen Gendel ofGendeLLindheim BioCom Partners, +1-212-918-4650, for PeregrinePharmaceuticals, Inc.
